Research and Development

An experienced pharmaceutical development team

Research and Development

At GMPO our research and development strategy is focused on the patient. Our mission is to identify and develop innovative therapies for patients, in the hope of making a meaningful difference to their lives.

We only work in rare diseases with an unmet medical need. There are over 7,000 known rare diseases. We have selected to develop our first product in Wilson’s Disease, a disease affecting 1 in every 30,000 of the population. Cuprior is an innovative formulation, that has the potential to offer new options to patients.

We have a network of world experts and work with scientists, academic institutions and companies with innovative technologies and products to enable their development and commercialization.

Cuprior Development

EU – Patients intolerant to D-Penicillamine
US – Patients intolerant to D-Penicillamine

RegionPreclinicalPhase 1Phase 2Phase 3FilingApproval
Approval Stage
Phase 3 Development

Get In Touch

Find out more about GMPO, who we are and what we do.

Start typing and press Enter to search

Hello. Add your message here.